Abstract
A variety of DNA-based methods of modulating the immune and/or inflammatory response in animal models of asthma have shown significant promise. Antisense strategies seek to inhibit expression of specific host genes, whereas DNA vaccines aim to modulate the immune response to specific encoded allergens. In contrast, ISS DNA therapy seeks to redirect the host immune response from a Th2 to a Th1 response. Current human studies will help to determine which, if any, of these DNA based therapies is a safe and effective therapy for human asthma.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
